Pharmacogenomics · 2017
DNA variants in DHFR gene and response to treatment in children with childhood B ALL: revisited in AIEOP-BFM protocol.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ceppi Francesco, Gagné Vincent, Douyon Laurance, Quintin Camille J, Colombini Antonella, Parasole Rosanna, Buldini Barbara, Basso Giuseppe, Conter Valentino, Cazzaniga Giovanni, Krajinovic Maja
Аннотация
AIM: We have previously reported an association of dihydrofolate reductase promoter polymorphisms with reduced event-free survival in childhood acute lymphoblastic leukemia (ALL) patients treated with Dana Farber Cancer Institute protocol. Here, we assessed whether these associations are applicable to other protocol, based on different methotrexate doses.
METHODS: Genotypes for six tag polymorphisms and resulting haplotypes were analyzed for an association with ALL outcome.
RESULTS: The association was found with the polymorphisms A-680C, A-317G and C-35T in high-risk group patients. Carriers of haplotype *1 had a remarkably higher risk of events compared with noncarriers and a lower probability of event-free survival (21.4 vs 81.3%).
CONCLUSION: The role of DHFR variants in predicting the outcome of childhood ALL extends beyond single-treatment protocol and can be useful biomarker in personalizing treatment.
METHODS: Genotypes for six tag polymorphisms and resulting haplotypes were analyzed for an association with ALL outcome.
RESULTS: The association was found with the polymorphisms A-680C, A-317G and C-35T in high-risk group patients. Carriers of haplotype *1 had a remarkably higher risk of events compared with noncarriers and a lower probability of event-free survival (21.4 vs 81.3%).
CONCLUSION: The role of DHFR variants in predicting the outcome of childhood ALL extends beyond single-treatment protocol and can be useful biomarker in personalizing treatment.
Предметные рубрики MeSH
Antineoplastic Combined Chemotherapy ProtocolsAsparaginaseBiomarkers, TumorChildDNADaunorubicinDisease-Free SurvivalFemaleHaplotypesHumansMaleMethotrexatePolymorphism, GeneticPrecursor Cell Lymphoblastic Leukemia-LymphomaPrednisonePromoter Regions, GeneticTetrahydrofolate DehydrogenaseTreatment OutcomeVincristine